Focus on Metastatic Colorectal Cancer: Insights and Strategies to Refine Patient Care

This comprehensive program gathers insight from 5 experts to improve the skills of clinicians who treat patients with metastatic CRC, featuring education enhanced by practical tools for applying new findings in the clinic. All aspects of this program are designed to complement each other, including an Interactive Treatment Decision Aid, an expert-authored module, expert commentaries, and downloadable slidesets.
Tanios Bekaii-Saab, MD, FACP
Program Director
Tanios Bekaii-Saab, MD, FACP
George A. Fisher, MD, PhD
Scott Kopetz, MD, PhD, FACP
John Strickler, MD
Alan P. Venook, MD

ClinicalThought

BRAF-mutated CRC has a poor prognosis and limited treatment options. Read my thoughts on how combinations with BRAF inhibitors are offering promising benefits for this challenging population.

Scott Kopetz, MD, PhD, FACP Released: August 14, 2017

As patients progress through first-line and second-line therapy, selection of therapy becomes more complicated and nuanced. Here’s how I navigate the multiple treatment options.

John Strickler, MD Released: September 11, 2017

In this commentary on the treatment of metastatic colorectal cancer, I explore areas of consensus and controversy among experts including management of MSI-high/MMR-deficient tumors, treatment of transverse primaries, management of tumors with BRAF V600E mutations, and approaches in later lines of therapy.

Tanios Bekaii-Saab, MD, FACP Released: October 31, 2017

In this case study from my clinic on the treatment of a new mother with metastatic colon cancer, I explore her questions, options, therapy selection, and follow-up.

Alan P. Venook, MD Released: January 11, 2018

Interactive Tool

This interactive treatment decision aid will let you compare your choice of therapy for patients with metastatic CRC with expert recommendations from Tanios Bekaii-Saab, MD, FACP; George A. Fisher, MD, PhD; Scott Kopetz, MD, PhD, FACP; John Strickler, MD; and Alan P. Venook, MD.

Tanios Bekaii-Saab, MD, FACP
Program Director
George A. Fisher, MD, PhD Scott Kopetz, MD, PhD, FACP John Strickler, MD Alan P. Venook, MD
Released: October 17, 2017

Module

In this CME/CE-certified activity, Tanios Bekaii-Saab, MD, FACP, reviews key data supporting evolving treatment choices for patients with metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, FACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: November 21, 2017 Expiration: November 20, 2018

In this downloadable slideset, Tanios Bekaii-Saab, MD, FACP, reviews current management strategies for patients with metastatic CRC along with key data supporting each approach.

Released: November 21, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by educational grants from
Bayer Healthcare Pharmaceuticals Inc.
Genentech
Lilly
Taiho Pharmaceuticals

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?